Recently, Jiangsu Pacific Meinuoke Biopharmaceutical Co, Ltd. was approved to establish the Jiangsu Antibody Drug Engineering Center .

Pacific Meinuoke and the Research Center for Cell Engineering of the No.4 Military Medical University will make joint efforts to build this center. A total of RMB 10 million will be invested on the construction of the technological laboratory and the pilot production plant of mammalian cell culture with a capacity of 5L -300L .

After completion, thisantibody drug engineering center will become a one-stop R&D service platform, which will make breakthroughs in the development of modern biotechnology industry, and thus speed up the industrialization process of China-made antibody therapeutics.